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Once-daily Truvada (Emtricitabine/Tenofovir) as a method of pre-exposure prophylaxis (PrEP) 
is one of the most promising biomedical interventions to eliminate new HIV infections; however, 
uptake among gay, bisexual, and other men who have sex with men has been slow amidst 
growing concern in popular/social media that PrEP use will result in reduced condom use (i.e., 
risk compensation). We investigated demographic, behavioral, and psychosocial differences in 
willingness to use PrEP as well as the perceived impact of PrEP on participants’ condom use in a 
sample of 206 highly sexually active HIV-negative gay and bisexual men. Nearly half (46.1%) 
said they would be willing to take PrEP if it were provided at no cost. Although men willing to 
take PrEP (vs. others) reported similar numbers of recent casual male partners (< 6 weeks), they 
had higher odds of recent receptive condomless anal sex (CAS)—i.e., those already at high risk 
of contracting HIV were more willing to take PrEP. Neither age, race/ethnicity, nor income were 
associated with willingness to take PrEP, suggesting equal acceptability among subpopulations 
that are experiencing disparities in HIV incidence. There was limited evidence to suggest men 
would risk compensate. Only 10% of men who had not engaged in recent CAS felt that PrEP 
would result in them starting to have CAS. Men who had not tested for HIV recently were also 
significantly more likely than others to indicate willingness to take PrEP. Offering PrEP to men 
who test infrequently may serve to engage them more in routine HIV/STI testing and create a 
continued dialogue around sexual health between patient and provider in order to prevent HIV 
infection. 






Tomar  Truvada (Emtricitabine/Tenofovir) una vez al día como un método de Profilaxis Pre- 
Exposición (PrEP) es una de las intervenciones biomédicas más prometedoras para eliminar 
nuevas infecciones del VIH; pero igual,  el crecimiento del uso de Truvada has sido lento entre 
hombres que tienen sexo con hombres por la preocupación en medios de comunicación 
populares/sociales que PrEP resultará  en una reducción en el uso de condones. Investigamos 
diferencias demográficas, de conducta y psicosociales en la disposición para usar PrEP y también 
el impacto percibido que PrEP podría tener sobre el uso de condones en una muestra de 206 
hombres gay y bisexuales que son altamente  activos sexualmente. Casi la mitad (46.1%) dijeron 
que tomarían PrEP si fuese posible tomarlo sin ningún costo. Aunque los hombres que tienen 
disposición a tomar PrEP reportaron números similares de parejas sexuales varones y recientes 
(< 6 semanas), éstos tuvieron más incidentes recientes de sexo sin condón receptivo  (SSC) – 
esto da a entender que los hombres que ya están en alto riesgo de contraer el VIH están más 
dispuestos a tomar PrEP. Ni la edad, raza/etnicidad, o sueldo personal fueron asociados con ser 
dispuesto a tomar PrEP, esto sugiere que hay aceptación igual entre subgrupos de población 
experimentando desigualdades en incidencia del VIH. Hubo evidencia limitada para sugerir que 
los hombres aumentarían su riesgo porque ya están protegidos por PrEP. Solamente 10% de 
hombres que no han tenido SSC sintieron que PrEP resultaría en comenzar a tener SSC. Los 
hombres que no se han realizado la prueba para el VIH recientemente también fueron 
considerablemente más probables que otros en indicar disposición para tomar PrEP. Ofrecer 
PrEP a los hombres que se hacen la prueba para el VIH con infrecuencia puede servir en 
enlazarlos más en la realización de las pruebas de VIH/ETS de manera rutinaria y crear un  
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diálogo continuo sobre la salud sexual entre paciente y proveedor para prevenir la infección con 




More than three decades into the HIV/AIDS epidemic, researchers have described our 
HIV prevention efforts as stalled.
1
 In spite of representing between 2-5% of the population,
2
 gay, 
bisexual, and other men who have sex with men (GBMSM) make up an estimated 65% of new 
HIV infections.
3
 In recent years, incidence has plateaued among GBMSM overall; however, in 
some sub-populations such as GBMSM of color, it has increased dramatically.
4
 In 2010, the 
Iniciativa Profilaxis Pre-Exposición (iPrEX) study released the first set of results from their 
ongoing trial of once-daily Truvada (Emtricitabine/Tenofovir) as a method of pre-exposure 
prophylaxis (PrEP). These initial results found PrEP to reduce the likelihood of HIV infection in 
GBMSM by 44%.
5
 However, further examination of the results has noted that, among those with 
detectable levels of the drug in their system, HIV infections were reduced by 92%.
5
 All said, 
PrEP remains one of the most promising biomedical interventions to eliminate new HIV 
infections in populations who are at high risk of contracting HIV.
6
 In a simulation study, PrEP 
was shown to prevent 29% of new HIV infections over a 20-year time horizon.
7
 Both the CDC 
and WHO have recommended that GBMSM consider PrEP as part of their HIV prevention 
plan.
8,9
 Specifically, the CDC has recommended PrEP to GBMSM at high risk of acquiring 
HIV,
9
 whereas, WHO recommended that all GBMSM consider the use of PrEP while still 
continuing to use condoms.
8
  
 Since the Food and Drug Administration (FDA) approved PrEP for HIV prevention in the 
United States in 2012, popular media has indicated that awareness of PrEP has been low and roll 
out has been slow.
6,10,11
 Although studies have reported that PrEP naive GBMSM are interested 
in using PrEP once they are educated about the HIV prevention tool,
12,13
 a 2014 study reported 
that after educating 416 HIV-negative GBMSM about PrEP at a testing facility, only 2 (0.47%) 
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accepted the offer of a prescription.
14
 Between January 2011 and March 2013, only 1,774 HIV-
negative people in the U.S. had filled prescriptions for PrEP, many of which were women.
15
  
Several reasons have been proposed for the slow uptake of PrEP, though limited 
empirical evidence exists. Some have suggested it may be due to cost concerns,
16,17
 given that an 
annual prescription of Truvada can exceed $12,000 for those without health insurance or 
prescription coverage. In addition, even for those with insurance, high copayments may also 
serve as a deterrent.
18
 Others have suggested it may be a combination of lack of awareness that 
one may be an appropriate candidate for PrEP
19
 coupled with the belief that PrEP is only for men 
who are very risky.
19
  GBMSM have also expressed a concern about social stigma attached to 
taking PrEP—fear of what family or friends may think about the choice to take the 
medication.
7,20-22
 Provider-initiated barriers have also been proposed as responsible for the slow 
uptake.
23
 To our knowledge, educational attainment is the only demographic characteristic to be 
associated with acceptability of PrEP. In prior research, higher educational attainment was 
positively correlated with PrEP acceptability.
6,24
  
For providers, researchers, and among gay and bisexual communities, there is an ongoing 
question as to whether taking PrEP will result in GBMSM reducing their condom use
20,25
 via risk 
compensation (i.e., biological risks are decreased by PrEP and so behavioral risks are increased). 
In contrast to messages being spread via popular and social media,
26
 empirical data suggest the 
potential for risk compensation is low. For example, when a sample of GBMSM, all of whom 
had reported condomless anal sex (CAS), were presented with hypothetical situations about PrEP 
use, 35.5% of men said they would reduce their condom use if PrEP was 80% effective.
24
  
 For the current study, we investigated demographic, behavioral, and psychosocial 
differences in willingness to use PrEP, as well as the perceived impact of PrEP on participants’ 
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condom use. Our sample included highly sexually active gay and bisexual men—individuals 
who meet WHO and CDC recommendations as candidates for PrEP. To our knowledge, there are 
no published studies on willingness to use PrEP as well as the perceived impact of PrEP on 
condom use with this population. As an exploratory study, we did not have a priori hypotheses. 
With the continued expansion and uptake of PrEP among populations at high risk of HIV 
acquisition, such findings can be useful for providers and research both in terms of the 
characteristics associated with willingness to use PrEP, as well as perceived impact of PrEP on 
future condom use.  
Method 
Analyses for this manuscript were conducted on data from The Pillow Talk Project, a 
longitudinal study of highly sexually active (i.e., ≥ 9 male partners in 90 days) gay and bisexual 
men in New York City (NYC).
27
 For the purposes of this project, we operationalized highly 
sexually active as having at least 9 sexual partners in the 90 days prior to enrollment. This 
criterion was based on prior research,
28-30
 including a probability-based sample of urban 
GBMSM
31,32
 that found 9 partners was 2 to 3 times the average number of sexual partners among 
sexually active GBMSM. By definition, every participant for the present analysis would have 
met eligibility criteria for the iPrEX trial, as well as CDC and WHO recommendations for 
starting PrEP. 
Recruitment procedures have been described elsewhere.
33
 In brief, we utilized a 
combination of strategies: (1) respondent-driven sampling; (2) Internet-based advertisements on 
social and sexual networking websites; (3) email blasts through New York City gay sex party 
listservs; and (4), active recruitment in New York City venues such as gay bars/clubs, 
concentrated gay neighborhoods, and ongoing gay community events. 
10 
 
Enrollment began in February 2011 and closed in June 2013. The project enrolled both 
HIV-negative and HIV-positive men, though the analyses for this manuscript were limited to 
HIV-negative men. Of the 377 men who enrolled in the project, 208 (55.2%) were confirmed to 
be HIV-negative with a rapid HIV antibody test during their assessment. Two of these men were 
missing responses on key variables for this study; thus, the present analysis focused on the 
remaining 206 HIV-negative gay and bisexual men. 
Participants and Procedures 
Participants completed a phone-based screening interview to assess eligibility, which was 
defined as: at least 18 years of age; biologically male and self-identified as male; nine or more 
male sexual partners in the prior 90 days; self-identification as gay, bisexual, or some other non-
heterosexual identity (e.g., queer); and daily access to the Internet (which was required for a 
portion of the study not discussed in this manuscript). Participants who met preliminary 
eligibility were emailed a link to an Internet-based computer-assisted self-interview (CASI), 
which included informed consent procedures. Men completed this one-hour online survey at 
home followed by an in-person baseline appointment. Final eligibility and enrollment was 
confirmed during the in-person appointment.  
All procedures were reviewed and approved by the Institutional Review Board of the 
City University of New York.  
Measures 
 Measures used for this manuscript were taken from the baseline assessment. Using a 
computer-assisted survey, participants reported demographic characteristics, including sexual 
identity, age, race/ethnicity, education, and relationship status. Participants completed the 
Hypersexual Disorder Screening Inventory (HDSI,  = 0.89),34 the Temptation for Unsafe Sex 
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Scale ( = 0.95),34 the Safer Sex Self-Efficacy Questionnaire ( = 0.97),20,35 and the Decisional 
Balance (Pros & Cons) for Sex Without Condoms
36-38
 which includes a subscale to measure 
perceived benefits to not using condoms (e.g., “sex without a condom is more spontaneous,”  = 
0.86), and a subscale to measure perceived negative consequences from not using condoms (e.g., 
“having sex without a condom could cause me to get an STD,”  = 0.81). The HSDI39 is a seven 
item scale divided into two sections. Both sections include the prompt “Please rate how often 
each item is true or how accurately it describes your sexual behavior during the last 6 months.” 
Section A contains five items measuring recurrent and intense sexual fantasies, urges, and 
behaviors. Section B consists of two items measuring distress and impairment as a result of these 
fantasies, urges, and behaviors. Responses (0 = Never true to 4 = Almost always true) were 
summed to provide a score ranging from 0 to 28. Responses of 3 or 4 are recoded as 
endorsement whereas 0, 1, or 2 are coded as non-endorsement. Participants were considered to 
have screened positive for hypersexual disorder if they endorsed at least four items in Section A 
and at least one item in Section B.     
 Sexual behavior. During the in-person assessment, participants completed an 
interviewer-administered structured timeline follow-back (TLFB) interview
40,41
 which involved 
completing a detailed calendar of their sexual events in the 42 days (6 weeks) prior to the study 
visit. We generated summary scores for a variety of sexual behaviors (e.g., number of male 
partners, number of male serodiscordant partners, insertive anal sex without a condom (yes, no), 
receptive anal sex without a condom (yes, no)). 
Pre-Exposure Prophylaxis. Participants were presented with the following brief 
summary of PrEP:  
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“PrEP (pre-exposure prophylaxis) is a new biochemical strategy to prevent HIV 
infection. PrEP involves HIV-negative guys taking anti-HIV medications (for example, 
Truvada) once a day, every day to reduce the likelihood of HIV infection if they were 
exposed to the virus. The first clinical trial of PrEP indicated that it reduced the 
likelihood of HIV infection when used in combination with other preventative methods, 
such as condoms.”  
Participants then responded to a series of questions including, how likely they would be to take 
PrEP if it were offered to them for free (“would definitely,” “would probably,” “might,” “would 
probably not,”  “would definitely not”), and how familiar they were with PrEP (dichotomized 
into 0 = never heard of before, 1 = heard of before). Those who said they would probably or 
definitely take it were coded as having a high willingness to take PrEP in these analyses (0 = no, 
1 = yes).  
Men were also asked if taking PrEP would influence their condom use (“significantly 
more likely,” “somewhat more likely,” “would not change,” “somewhat less likely,” “significantly 
less likely.” This variable was trichotomized (-1 = decrease use, 0 = no change, 1 = increase use)  
Analytic Plan 
 In the first set of analyses, we compared men who were willing vs. unwilling to take 
PrEP. In the second set, we compared the perceived impact of PrEP on men’s condom use (i.e., 
risk compensation). For both sets of analyses participants were compared based on demographic 
characteristics, psychosocial measures, and sexual behavior. When appropriate, Chi-square, t-
tests, Mann-Whitney U, and Kruskal-Wallis tests were used. Finally, we conducted a forward 
and backward logistic regression to determine independent associations with the belief that PrEP 
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would reduce one’s condom use (1 = yes, 0 = no). Variables selected for the model were taken 
from those that were significant (p < .05) at the bivariate level (shown in Table 3). 
Results 
 As can be seen in Table 1, the sample was diverse with regards to race and ethnicity, 
employment status, and educational achievement, while a majority of the sample was gay-
identified and single. Average age was 34 (SD = 11.8). Eighteen percent were currently in a 
relationship and two-thirds of the sample self-reported a lifetime STI diagnosis, with gonorrhea, 
chlamydia, and genital warts being the most common. Participants reported a median of 11 
casual male partners (IQR 7 to 17) in the last 42 days (6 weeks). 
-Table 1- 
 Participants’ familiarity with PrEP was significantly associated with the year in which 
they enrolled: nearly half (47.0%) of participants enrolled in 2011 said they had never heard of 
PrEP, compared with 37.8% among men enrolled in 2012, and only 27.6% in 2013, Mantel-
Haenszel 2 (1) = 6.06, p =.01; Pearson 2(4) = 9.61, p = .047.  However, willingness to take 
PrEP if it was provided for free (p = .97) and the perceived impact of PrEP on one’s condom use 
(p = .26) did not significantly change over time. Overall, nearly half (46.1%) of participants said 
they would be willing to take PrEP if it was provided for free. And, 23.1% said they believed it 
would decrease their condom use, 62.6% said their condom use would stay the same, and 14.1% 
said they would increase their condom use if on PrEP.  Six men (2.9%) said they had taken PrEP 
at one point in their lives. See Figure 1. 
-Figure 1- 
 Table 2 displays factors associated with willingness to take PrEP if it were provided at no 
cost and Table 3 reports on the perceived impact of PrEP on condom use. Willingness to take 
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PrEP was not significantly associated with age, race/ethnicity, income, being in a relationship, 
anal sexual role (e.g., top, bottom, versatile), self-identifying as a barebacker, temptations for 
CAS, perceptions of the drawbacks of CAS, self-efficacy for condom use, or the number of male 
sex partners in the last 42 days. Men who indicated willingness to take PrEP perceived 
significantly greater benefits of engaging in CAS. Compared with men who indicated low 
willingness to take PrEP, a significantly larger proportion of men willing to take PrEP last tested 
for HIV more than 6 months ago, reported recent receptive CAS, and screened positive for 
hypersexual disorder. Compared with men who indicated low willingness to take PrEP, a 
significantly smaller proportion of men who indicated willingness to take PrEP had a college 
education. Although not significant (p = .06), there was a trend between perceived impact of 
PrEP on condom use and willingness to start PrEP—in total, 65.5% of men who said PrEP would 
increase their condom use expressed willingness to take PrEP compared with only 47.9% of 
those who felt that PrEP would decrease their condom use and 41.1% of men who felt that PrEP 
would have no impact on their condom use.  
-Table 2- 
 The perceived impact of PrEP on condom use was not significantly associated with being 
in a relationship, recency of HIV testing, hypersexual disorder, or anal sexual role. It was 
associated with age, race/ethnicity, and income (see Table 3). Men who believed PrEP would 
decrease their condom use also reported significantly higher levels of temptation to engage in 
CAS and higher perceived benefits to engaging in CAS, and lower perceived drawbacks to 
engaging in CAS. Compared to men who felt PrEP would have no impact on their condom use, 
men who believed PrEP would decrease their condom use also reported a greater number of male 
partners. Furthermore, one-third of men who engaged in recent CAS believed that PrEP would 
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decrease their condom use, compared to only 10% of men who did not report recent CAS. Men 
who perceived that PrEP would have no impact on their condom use reported significantly 
higher levels of self-efficacy for condom use.  
-Table 3- 
Finally, we conducted both forward and backward logistic regression to determine 
independent associations with the belief that PrEP would reduce one’s condom use (1 = yes, 0 = 
no). Variables selected for the model were taken from those that were significant (p < .05) at the 
bivariate level (shown in Table 3). Both models converged on the same two variables: (1) CAS 
in the prior 42 days (AOR = 2.96, 95% CI = 1.82 – 6.85), and (2) increased scores on the 
Temptation for Unsafe Sex Scale (AOR = 1.04, 95% CI = 1.01 – 1.07).  
Discussion 
 Pillow Talk is a study of highly sexually active gay and bisexual men—individuals who, 
by definition, meet iPrex and CDC criteria/guidelines for PrEP treatment.
9,19
 In this study, nearly 
half of men said they would be willing to take PrEP if it were offered at no cost to them. 
Although men willing to take PrEP reported similar number of male partners in the prior 6 
weeks, they had higher odds of reporting recent receptive CAS. In essence, those already at high 
risk of contracting HIV were significantly more willing to take PrEP. These men also had higher 
odds of screening positive for hypersexual disorder, suggesting that they might be ideal targets 
for offering PrEP, as uptake among these men may be higher. 
This study found marked increase in knowledge of PrEP over time consistent with 
historical events (e.g., the release of iPrex results in 2011, FDA approval in 2012, and social 
media campaigns both for and against PrEP in 2013).
20-22
 Interestingly, although awareness of 
PrEP increased over time, willingness to use PrEP and the perceived impact of PrEP on condom 
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use did not change in this study. These findings suggest that although awareness of PrEP is 
increasing, willingness to use PrEP is not. It may be that stagnant willingness to start PrEP could 
be a result of individuals not recognizing that they would be appropriate candidates to start 
PrEP,
19
 or stigma attached to using PrEP.
42
 Likewise, the perceived impact of PrEP on condom 
use did not change over time. This too suggests that although awareness of PrEP is increasing, 
this increased knowledge about PrEP has not altered men’s attitudes about condom use.  
 Neither age, race/ethnicity, nor income were associated with willingness to take PrEP, 
suggesting equal PrEP acceptability among GBMSM subpopulations that are experiencing 
disparities in HIV incidence (e.g., younger men, men of color). That being said, the question 
assessing willingness to take PrEP was phrased regarding PrEP if it was available for free. 
Although many insurance plans, including Medicaid, cover Truvada and, at the moment, Gilead 
(the manufacturer of Truvada) provides a coupon that will cover much—if not all—of a person’s 
copayment (gileadcopay.com). It is unclear how many men in this study may have been 
dissuaded from starting PrEP due to cost concerns. The reality is that PrEP may effectively be 
free or low cost for many individuals; however, it remains important to ensure individuals are 
properly engaged in primary care and are aware of the avenues by which PrEP is available to 
them at low cost or for free.  
Men with less than a college education were more likely than others to consider taking 
PrEP, which is inconsistent with prior research.
6,24
 It may be that those with more education are 
reading more about PrEP and have greater concerns regarding efficacy, adherence, and stigma. 
Alternately, this may be a result of the unique nature of the population from which we sampled 
(highly sexually active). In either event, our findings highlight the need to investigate the 
association between education and willingness to use PrEP. As a biomedical strategy, PrEP 
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involves navigating health care systems (e.g., primary care, testing for HIV and kidney function, 
prescription coverage) coupled with behavioral methods of HIV and STI prevention (e.g., 
condom use). Level of education is related to health literacy
37
 and thus should be monitored with 
regard to PrEP uptake, adherence, and effectiveness. 
Men who had not tested recently were also more likely to indicate willingness to take 
PrEP than others. Guidelines for PrEP treatment indicate that providers retest for HIV every 
three to four months before they renew a patient’s prescription, along with providing behavioral 
risk reduction support, assessment for both side effects and STI symptoms, and medication 
adherence counseling.
9
 Offering PrEP to men who test infrequently may serve to engage them 
more in routine HIV and STI testing, create a continued dialogue around sexual health between 
patient and provider, and prevent HIV infection.   
 In popular and social media there has been significant debate about the impact of PrEP on 
CAS, often suggesting that men’s condom use will decrease as a result of initiating PrEP.
20,21,43
 
In contrast to these hypotheses regarding the potential for risk compensation, this study builds on 
prior work refuting risk compensation. For example, a previous study of GBMSM reporting CAS 
in NYC,
24
 found that only 35.5% of men would reduce their condom use if PrEP was 80% 
effective, and only 23.3% of men in our study believed their condom use would decrease. 
Further, our results suggest that only 10% of men who had not engaged in recent CAS felt that 
PrEP would result in them starting to have CAS. That is, 90% of men who abstained from CAS 
felt their condom use would remain the same or increase.  
Importantly, those who felt their risk behaviors may increase as a result of PrEP were 
overwhelmingly those who were already engaging in behaviors that put them at risk for HIV. 
This suggests that PrEP may be a more effective HIV prevention option for these men regardless 
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of potential increases in CAS given the already inconsistent nature of their condom use. With 
adequate medication adherence, these men would be protected both during times when they are 
already engaging in risk behavior, as well as during any potential additional risk behavior 
resulting from PrEP initiation, whereas they are presently completely unprotected during all acts 
of risk behavior (hold for viral suppression among any undetectable HIV-positive partners). To 
protect these men from contracting and transmitting STIs, it would be additionally vital to 
regularly test and treat for the full range of STIs, (including blood, urethral, rectal, and 
pharyngeal screening), as well as vaccinate for HPV and hepatitis A and B. Further, it remains 
unknown as to whether the presence of an STI—which serves as a highly effective route for HIV 
to pass between partners—would decrease the ability of PrEP to prevent seroconversion by 
virtue of greater exposure to the virus at a given time.  
Our study found that the perceived impact of PrEP on condom use was associated with 
several important demographic characteristics including age, race, income, and education. With 
the exception of age, the associations observed with other demographic characteristics suggest 
that the most vulnerable men would not change their condom use or, in fact, would increase it. 
This includes men of color, men with lower income, and men with less than a college education. 
We did find, however, that men under the age of 40 were more likely than those over 40 to say 
that their condom use would decrease. This may be a generational effect related to the history of 
the HIV epidemic. Men over 40 came of age during the height of the epidemic, while those 
under 40 came of age at a time when it was known how HIV was transmitted and effective 
treatment options were available.
44




The results of this study should be understood in light of their limitations. To be eligible 
for the Pillow Talk study, men had to report at least 9 male partners in the prior 90 days. This 
sample represents, by definition, ideal targets for PrEP; however, these men do not represent all 
gay and bisexual men. We used a variety of non-probability methods to recruit participants and, 
although respondent-driven sampling was among our methods, we lacked statistical power to 
assess for homophily or differences by recruitment method. Some measures were collected via 
online survey, which allowed men to complete the survey from the comfort of their homes and 
on their own schedule; however, we cannot know what types of distractions might have been 
drawing their attention away from the survey while they completed it. Data used in this analysis 
were cross-sectional, and behavioral measures were captured via the TLFB interview, which has 
demonstrated strong reliability and validity with a variety of populations. However, as a face-to-
face interview, there is the potential for bias due to socially desirable responses. We do not have 
data on reasons why individuals were unwilling to go on PrEP and our findings indicate the 
prevalence is large enough to warrant further consideration, perhaps through qualitative methods 
like semi-structured interviews and/or focus groups. The results of this study concerned 
hypothetical PrEP initiation. As PrEP continues to diffuse as a new prevention strategy, it is 
important to continue to investigate how gay and bisexual men who represent ideal targets for 
PrEP perceive its impact on their own sexual behavior.  
Conclusion 
 In a sample of highly sexually active gay and bisexual men, we found that knowledge of 
PrEP increased markedly between 2011 and 2013, however willingness to use PrEP as well as 
the perceived impact of PrEP on one’s own sexual behavior did not change. Willingness to use 
PrEP was not significantly associated with a number of key demographic characteristics, 
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suggesting that GBMSM subpopulations that are disproportionally impacted by HIV (e.g., young 
men of color) would be equally likely to consider PrEP. Nearly two-thirds of participants 
believed that their condom use would not change were they on PrEP, and a minority felt their 
condom use would decrease. Because being on PrEP requires one to see their care provider every 
three months, this can serve as an important opportunity to engage men in sexual health 
discussions and interventions to prevent onward STI transmission. Those who felt their risk 
behaviors may increase as a result of PrEP were overwhelmingly those who were already 
engaging in some degree of HIV transmission risk behavior. This suggests that PrEP may be a 
highly effective HIV prevention option for these men regardless of potential increases in CAS 
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Some high school/GED or less 13 6.3
Some college, associates degree, or currently in college 46 22.3
4-year college degree 84 40.8
Graduate school 63 30.6
Relationship status
In a relationship (e.g., married, boyfriend, lover) 38 18.4
I am casually dating 49 23.8
I am single 119 57.8
Ever experienced an STI (yes) 136 66.0
Chlamydia 56 27.2
Gonorrhea 68 33.0
Anal/genital warts/HPV 52 25.2
Genital herpes (HSV1/HSV2) 34 16.5
Syphillis 19 9.2
Hepatitis C 2 1.0





Table 2. Willingness to take PrEP if it were free 
n % n %  2 p
Age
18 to 29 45 50.6 44 49.4 1.61 0.66
30 to 39 33 55.9 26 44.1
40 to 49 20 62.5 12 37.5
50+ 13 50 13 50
Race or ethnicity
Black 17 60.7 11 39.3 2.06 0.56
Latino 10 43.5 13 56.5
White 69 55.6 55 44.4
Other 15 48.4 16 51.6
Income > $30K
No 44 48.4 47 51.6 2.07 0.16
Yes 67 58.3 48 41.7
4-year College education
No 24 40.7 35 59.3 5.80 0.02
Yes 87 59.2 60 40.8
Currently in a relationship
Yes 22 57.9 16 42.1 0.30 0.58
Recency of last HIV test
Less than 3 months 66 62.9 39 37.1 7.09 0.03
3-6 months ago 21 46.7 24 53.3
greater than 6 months 24 42.9 32 57.1
Anal sexual role
Top or versatile top 51 55.4 41 44.6 0.16 0.92
Versatile 22 52.4 20 47.6
Bottom or versatile bottom 38 52.8 34 47.2
Self-identified as a barebacker
Yes 5 45.5 6 54.5 0.32 0.56
Yes 9 32.1 19 67.9 6.16 0.01
Perceived impact of PrEP on my condom use
Decrease 25 52.1 23 47.9 5.77 0.06
No change 76 58.9 53 41.1
Increase 10 34.5 19 65.5
Sexual behavior, last 42 days (6 weeks) Mdn IQR Mdn IQR U p
Total # male partners 10 7-18 11 8-17 5476 0.63
Total # male serodiscordant partners
3
4 2-10 4 1-9 5101 0.69
n % n %  2 p
Sexual behavior, last 42 days (6 weeks)
Anal insertive, no condom
No 60 54.5 50 45.5 0.04 0.84
Yes 51 53.1 45 46.9
Anal receptive, no condom
No 85 59 59 41 5.1 0.02
Yes 26 41.9 36 58.1
Any condomless anal sex
No 51 57.3 38 42.7 0.74 0.39
Yes 60 51.3 57 48.7
M SD M SD t p
Temptation for unsafe sex scale, range 13-65 30.00 13.10 32.3 13.30 1.31 0.19
2.41 0.84 2.73 1.00 2.46 0.02
3.56 0.85 3.72 0.89 1.29 0.20
49.25 14.76 48.36 13.81 0.45 0.66
1
 "Might," "Probably not," "Definitely not"
2
 "Probably would," "Definitely would"
3 
Serodiscordant includes partners who were believed to be HIV-positive or of unknown HIV status
U  = Mann-Whitney U IQR = Interquartile range
Mdn = Median
Safer Sex Self-Efficacy Questionnaire, range 13-65
Decisional balance for sex without a condom (Pro), range 1-5
Decisional balance for sex without a condom (Con), range 1-5





n  = 111 n  = 95




Table 3. Perceived impact of PrEP on condom use
n % n % n %  2 p
Age
18 to 29 21 23.6 49 55.1 19 21.3 --
30 to 39 17 28.8 36 61 6 10.2
40 to 49 7 21.9 23 71.9 2 6.3
50+ 3 11.5 21 80.8 2 7.7
Age
18 to 39 38 25.7 85 57.4 25 16.9 6.49 0.04
40+ 10 17.2 44 75.9 4 6.9
Race or ethnicity
Black 3 10.7 20 71.4 5 17.9 --
Latino 4 17.4 12 52.2 7 30.4
White 32 25.8 87 70.2 5 4.0
Other 9 29 10 32.3 12 38.7
Race or ethnicity
non-White 16 19.5 42 51.2 34 29.3 26.00 < .001
White 32 25.8 87 70.2 5 4.0
Income > $30K
No 18 19.8 52 57.1 21 23.1 11.03 0.004
Yes 30 26.1 77 67.0 8 7.0
4-year College education
No 10 16.9 30 50.8 19 32.2 22.56 < .001
Yes 38 25.9 99 67.3 10 6.8
Currently in a relationship
Yes 6 15.8 26 68.4 6 15.8 1.48 0.48
Recency of last HIV test
Less than 3 months 28 26.7 60 57.1 17 16.2 3.02 0.55
3-6 months ago 10 22.2 30 66.7 5 11.1
greater than 6 months 10 17.9 39 69.6 7 12.5
Anal sexual role
Top or versatile top 20 21.7 60 65.2 12 13 0.58 0.97
Versatile 11 26.2 25 59.5 6 14.3
Bottom or versatile bottom 17 23.6 44 61.1 11 15.3
Self-identified as a barebacker
Yes 3 27.3 7 63.6 1 9.1 --
Yes 4 14.3 14 50.0 10 35.7 --
Sexual behavior, last 42 days (6 weeks) Mdn IQR Mdn IQR Mdn IQR K-W p post hoc
Total # male partners 14 10-18 10 7-17 9 6-12.5 7.769 0.02 A ≠ B
Total # male serodiscordant partners
1
4 2-9 4 1-11 4 1.5-8.5 0.163 0.92
n % n % n %  2 p
Sexual behavior, last 42 days (6 weeks)
Anal insertive, no condom
No 17 15.1 79 71.8 14 12.7 9.73 0.01
Yes 31 32.3 50 52.1 15 15.6
Anal receptive, no condom
No 28 19.4 93 64.6 23 16.0 4.57 0.10
Yes 20 32.3 36 58.1 6 9.7
Any condomless anal sex
No 9 10.1 67 75.3 13 14.6 15.74 < .001
Yes 39 33.3 62 53.0 16 13.7
M SD M SD M SD F p post hoc
Temptation for unsafe sex scale, range 13-65 38.12 10.10 27.98 12.71 33.17 15.40 11.83 < .001 A ≠ B
2.97 0.82 2.36 0.77 2.76 1.09 8.90 < .001 A ≠ B
3.45 0.74 3.63 0.90 3.98 0.84 3.45 0.03 A ≠ C
44.35 10.83 51.61 14.43 43.93 15.98 6.86 0.001 B ≠ A, C
-̀- Chi-square cannot be interpreted, expected counts fall below 5 in one or more cells
1 
Serodiscordant includes partners who were believed to be HIV-positive or of unknown HIV status
K-W = Kruskal-Wallace IQR = Interquartile range Mdn = Median
Decisional balance for sex without a condom (Con), range 1-5
Safer Sex Self-Efficacy Questionnaire, range 13-65
n  = 48 n  = 129
Hypersexual disorder screening inventory (HDSI) diagnosis
Group A Group B Group C
Decisional balance for sex without a condom (Pro), range 1-5
Perceived impact of PrEP on my condom use
Decrease No change Increase























% heard of PrEP % would take PrEP % says condom use
would decrease on PrEP
2011 (n = 66) 2012 (n = 111) 2013 (n = 29)
Year in which data were collected
p < .05 p = .97
p = .26
Figure 1. Changes in PrEP familiarity, uptake, and the perceived impact of PrEP
on condom use between 2011 and 2013
